![Clinical medicine / Cancer / Medicine / Cancer treatments / Organofluorides / Angiogenesis inhibitors / Eli Lilly and Company / Bevacizumab / FOLFIRI / FOLFOXIRI / Chemotherapy regimen / Cetuximab Clinical medicine / Cancer / Medicine / Cancer treatments / Organofluorides / Angiogenesis inhibitors / Eli Lilly and Company / Bevacizumab / FOLFIRI / FOLFOXIRI / Chemotherapy regimen / Cetuximab](https://www.pdfsearch.io/img/59489f98ce00d9b6624dc191e18e063c.jpg) Date: 2016-07-02 18:03:03Clinical medicine Cancer Medicine Cancer treatments Organofluorides Angiogenesis inhibitors Eli Lilly and Company Bevacizumab FOLFIRI FOLFOXIRI Chemotherapy regimen Cetuximab | | References [1] R. A. Adams, A. M. Meade, A. Madi, D. Fisher, E. Kay, S. Kenny, R. S. Kaplan, and T. S. Maughan. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC Add to Reading ListSource URL: www.toumiak.comDownload Document from Source Website File Size: 351,52 KBShare Document on Facebook
|